Gelteq Limited Ordinary Shares (GELS)vsZoetis Inc (ZTS)
GELS
Gelteq Limited Ordinary Shares
$0.57
-1.67%
HEALTHCARE · Cap: $5.97M
ZTS
Zoetis Inc
$75.02
-3.22%
HEALTHCARE · Cap: $32.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 2018764% more annual revenue ($9.53B vs $471,800). ZTS leads profitability with a 27.7% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 58/100 (C).
GELS
Avoid33
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GELS.
Margin of Safety
+11.5%
Fair Value
$145.41
Current Price
$75.02
$70.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 48.9% year-over-year
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
Trading at 9.6x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : GELS
The strongest argument for GELS centers on Price/Book, Revenue Growth. Revenue growth of 48.9% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : GELS
The primary concerns for GELS are EPS Growth, Market Cap, Profit Margin.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
GELS profiles as a hypergrowth stock while ZTS is a declining play — different risk/reward profiles.
GELS is growing revenue faster at 48.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZTS scores higher overall (58/100 vs 33/100), backed by strong 27.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gelteq Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. The company is headquartered in Caulfield, Australia.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?